You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
益佰製藥(600594.SH):擬以8.8億元購買京福華越和京福華採優先級財產份額 獲得旗下優良醫療服務資產
格隆匯 12-12 17:05

格隆匯 12 月 11日丨益佰製藥(600594.SH)公佈,公司擬以自有資金人民幣8.8元受讓華寶信託有限責任公司(“華寶信託”)持有的京福華越(台州)資產管理中心(有限合夥)(“京福華越”)66.54%的有限合夥人財產份額(對應出資額36666萬元)及京福華採(台州)資產管理中心(有限合夥)(“京福華採”)66.65%的有限合夥人財產份額(對應出資額42526萬元),同時盛世景資產管理集團股份有限公司(盛世景”)或其控制的實體將擔任京福華越及京福華採的普通合夥人及基金管理人。

京福華越與京福華採是由華寶信託作為優先級有限合夥人、中國民生信託有限公司作為中間級有限合夥人、恆康醫療作為劣後級有限合夥人京福資產管理有限公司(“京福資產”)作為普通合夥人共同投資設立的併購基金,用於投資收購泗陽醫院、蘭考第一醫院、蘭考東方醫院和蘭考堌陽醫院。20201月、3京福華越與京福華採併購基金存續期屆滿,併發布了清算公告,鑑於清算期京福華越與京福華採資產未能變現,基金管理人無法開展實質性清算工作。20206月和9月,華寶信託以投資退出期滿為由,向浙江省台州市椒江區人民法院對京福華越與京福華採提起強制清算程序,法院裁定受理,目前,尚未進行財產分配。

次購買京福華越和京福華採優先級財產份額,獲得旗下優良醫療服務資產,與公司“一艦雙翼”的戰略目標契合,符合公司發展戰略,有利於整合資源,擴公司醫療服務資產規模,增加現金流提升公司競爭力,實現公司可持續發展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account